JP6783247B2 - ガン予防における短鎖脂肪酸の使用 - Google Patents

ガン予防における短鎖脂肪酸の使用 Download PDF

Info

Publication number
JP6783247B2
JP6783247B2 JP2017557279A JP2017557279A JP6783247B2 JP 6783247 B2 JP6783247 B2 JP 6783247B2 JP 2017557279 A JP2017557279 A JP 2017557279A JP 2017557279 A JP2017557279 A JP 2017557279A JP 6783247 B2 JP6783247 B2 JP 6783247B2
Authority
JP
Japan
Prior art keywords
cancer
acid
pharmaceutically acceptable
hbx
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017557279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504457A5 (https=
JP2018504457A (ja
Inventor
ファイテルソン，マーク・エー．
ヘイス，エレナ・エミ．ジェー．ぺー．ヴェー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018504457A publication Critical patent/JP2018504457A/ja
Publication of JP2018504457A5 publication Critical patent/JP2018504457A5/ja
Application granted granted Critical
Publication of JP6783247B2 publication Critical patent/JP6783247B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)
JP2017557279A 2015-01-23 2016-01-21 ガン予防における短鎖脂肪酸の使用 Active JP6783247B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106778P 2015-01-23 2015-01-23
US62/106,778 2015-01-23
PCT/US2016/014292 WO2016118730A1 (en) 2015-01-23 2016-01-21 Use of short chain fatty acids in cancer prevention

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020176442A Division JP2021020929A (ja) 2015-01-23 2020-10-21 ガン予防における短鎖脂肪酸の使用

Publications (3)

Publication Number Publication Date
JP2018504457A JP2018504457A (ja) 2018-02-15
JP2018504457A5 JP2018504457A5 (https=) 2019-02-28
JP6783247B2 true JP6783247B2 (ja) 2020-11-11

Family

ID=56417737

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017557279A Active JP6783247B2 (ja) 2015-01-23 2016-01-21 ガン予防における短鎖脂肪酸の使用
JP2020176442A Pending JP2021020929A (ja) 2015-01-23 2020-10-21 ガン予防における短鎖脂肪酸の使用
JP2022196339A Pending JP2023027219A (ja) 2015-01-23 2022-12-08 ガン予防における短鎖脂肪酸の使用
JP2024220908A Pending JP2025038120A (ja) 2015-01-23 2024-12-17 ガン予防における短鎖脂肪酸の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020176442A Pending JP2021020929A (ja) 2015-01-23 2020-10-21 ガン予防における短鎖脂肪酸の使用
JP2022196339A Pending JP2023027219A (ja) 2015-01-23 2022-12-08 ガン予防における短鎖脂肪酸の使用
JP2024220908A Pending JP2025038120A (ja) 2015-01-23 2024-12-17 ガン予防における短鎖脂肪酸の使用

Country Status (12)

Country Link
US (6) US10231941B2 (https=)
EP (1) EP3247342B1 (https=)
JP (4) JP6783247B2 (https=)
KR (1) KR102735818B1 (https=)
CN (2) CN107405321A (https=)
AU (3) AU2016209244A1 (https=)
IL (1) IL253581A0 (https=)
MX (1) MX387817B (https=)
RU (1) RU2017127597A (https=)
SG (2) SG11201705953XA (https=)
WO (1) WO2016118730A1 (https=)
ZA (1) ZA201704977B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
ME03511B (me) 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2018089861A1 (en) * 2016-11-11 2018-05-17 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
EP3612570A4 (en) 2017-04-17 2021-01-13 The University of Chicago POLYMERIC MATERIALS FOR THE ADMINISTRATION OF SHORT-CHAIN FATTY ACIDS TO THE INTESTINE FOR HUMAN HEALTH AND DISEASE TREATMENT APPLICATIONS
US20220304967A1 (en) * 2017-04-24 2022-09-29 Allerpops Oral microbiota promoting composition cross-reference to related applications
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
MA51770A (fr) 2017-07-05 2020-05-13 Evelo Biosciences Inc Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis
CN111372477B (zh) * 2017-08-04 2024-05-24 雀巢产品有限公司 在含有gos的培养基中预调理的益生菌及其用途
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
CN110090230B (zh) * 2018-01-30 2022-07-12 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用
SG11202011031UA (en) * 2018-05-11 2020-12-30 4D Pharma Res Ltd Compositions comprising bacterial strains
SG11202011817WA (en) * 2018-06-01 2020-12-30 Evolve Biosystems Inc Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
EP4034096B1 (en) * 2019-09-25 2025-12-31 Philipps-Universität Marburg SHORT-CHAIN FATTY ACID PENTANOATE AS AN ACTIVATOR FOR CELL THERAPY AND ANTITUMOR THERAPY
KR102510198B1 (ko) * 2019-11-14 2023-03-15 가톨릭대학교 산학협력단 락토바실러스 속 균주 및 SCFA(Short fatty chain acid)를 포함하는 면역 질환의 예방 및 치료용 조성물
TWI734341B (zh) * 2020-01-14 2021-07-21 景岳生物科技股份有限公司 一種副乾酪乳桿菌ｇｍｎｌ-３４６用於抗口腔癌之用途
JP2023517869A (ja) * 2020-03-05 2023-04-27 リスキュア・バイオサイエンシーズ・カンパニー・リミテッド ロイコノストック属株を有効成分として含む癌の予防又は治療用医薬組成物
US20240009154A1 (en) * 2020-08-04 2024-01-11 Temple University-Of The Commonwealth System Of Higher Education Methods and compositions for treating cytokine release syndrome
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
JP2023549522A (ja) * 2020-11-12 2023-11-27 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション がん予防における短鎖脂肪酸の使用
WO2022177409A1 (ko) * 2021-02-22 2022-08-25 주식회사 리스큐어바이오사이언시스 류코노스톡 메센테로이데스 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2023141202A1 (en) * 2022-01-19 2023-07-27 Hodgdon Ian Short-chain fatty acids for cancer treatment
CN117925434B (zh) * 2022-10-26 2025-02-14 慕恩（广州）生物科技有限公司 粪肠球菌mnh 22871及其应用
CN116212027A (zh) * 2023-02-28 2023-06-06 西湖大学 一种调控Treg细胞内铁水平的试剂的用途
WO2025176152A1 (en) * 2024-02-19 2025-08-28 The University Of Hong Kong Probiotics mixtures and methods of use thereof for treating cancers
CN119424400B (zh) * 2024-10-21 2026-03-03 江南大学 缓解衰老的肠道菌群支链氨基酸代谢产物异丁酸和异戊酸及其应用
CN119258047A (zh) * 2024-11-26 2025-01-07 哈尔滨医科大学 琥珀酸在制备防治肝癌药物中的新用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735967A (en) 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
AU645070B2 (en) 1990-04-10 1994-01-06 Nb International Technologies Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94
PH31403A (en) 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
WO1995011699A1 (en) 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
JP2000072667A (ja) 1998-08-25 2000-03-07 Kurasuraa:Kk 大腸炎治療用経口投与剤
US6201077B1 (en) 1998-12-01 2001-03-13 Phillips Petroleum Company Process that produces polymers
EP1034788A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
EP1463759B8 (en) 2002-01-07 2013-07-10 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US8846039B2 (en) 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
JP2006501267A (ja) 2002-09-13 2006-01-12 バージニア コモンウェルス ユニバーシティー 白血病の処置のためのａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよびｂ）ヒストンデアセチラーゼインヒビターの組合せ剤
US20050023179A1 (en) 2003-07-31 2005-02-03 Albritton Charles Wade Fragile-product cage for vacuum packaging appliances
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
WO2007016953A1 (en) 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing alcohol induced liver cancer risk
EP2007370B1 (en) 2006-03-31 2013-12-18 Erasmus University Medical Center Rotterdam Novel composition for tumor growth control
WO2008054293A1 (en) * 2006-11-03 2008-05-08 Salutary Care Limited Composition, its use for treating systemic diseases a conditions, and product containing said composition
US20080153908A1 (en) 2006-12-20 2008-06-26 Jani Dharmendra M Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
CN101214234B (zh) * 2008-01-10 2010-09-08 中国人民解放军第二军医大学 α-羟基酸在制备癌瘤体内注射治疗药物中的应用
US9339667B2 (en) 2009-02-18 2016-05-17 Sea Qiq As Mixture of inorganic compounds, preparations containing the mixture and use of the mixture
EP3181134B1 (en) 2009-06-19 2019-10-30 DuPont Nutrition Biosciences ApS Bifidobacteria for treating diabetes and related conditions
US8962686B2 (en) 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
EP2389932A1 (en) 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
MX2013001190A (es) 2010-07-29 2013-03-18 Cosmo Technologies Ltd Composiciones farmaceuticas y/o dieteticas con base en acidos grasos de cadena corta.
SG183544A1 (en) 2010-11-29 2012-10-30 Univ Putra Malaysia Tumour cytotoxic agent and methods thereof
JP2014506923A (ja) * 2011-03-01 2014-03-20 クオラム イノベーションズ リミテッド ライアビリティ カンパニー 病原性バイオフィルムと関連した状態を治療するための物質および方法
WO2012131069A1 (en) 2011-03-31 2012-10-04 Proponent Biotech Gmbh Short chain fatty acids and their derivatives for use in treatment immunogenic disorders
US9402820B2 (en) * 2011-04-22 2016-08-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
SG11201402650RA (en) 2012-01-16 2014-06-27 Elizabeth Mckenna Compositions and methods for the treatment of hepatic diseases and disorders
GB201215289D0 (en) 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
TWI463986B (zh) 2012-08-29 2014-12-11 Univ China Medical 胚芽乳酸桿菌ｃｍｕ９９５菌株之新用途
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
EP3033091B1 (en) * 2013-08-16 2022-09-07 Versitech Limited Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma

Also Published As

Publication number Publication date
AU2019201799A1 (en) 2019-04-04
US11963938B2 (en) 2024-04-23
JP2023027219A (ja) 2023-03-01
KR20170128247A (ko) 2017-11-22
CA2974510A1 (en) 2016-07-28
SG11201705953XA (en) 2017-08-30
US20240342122A1 (en) 2024-10-17
EP3247342B1 (en) 2026-01-07
US10143669B2 (en) 2018-12-04
IL253581A0 (en) 2017-09-28
RU2017127597A3 (https=) 2019-07-17
CN115350171A (zh) 2022-11-18
SG10201907660YA (en) 2019-10-30
US20220008369A1 (en) 2022-01-13
JP2025038120A (ja) 2025-03-18
CN107405321A (zh) 2017-11-28
WO2016118730A1 (en) 2016-07-28
KR102735818B1 (ko) 2024-11-28
EP3247342A4 (en) 2018-10-10
RU2017127597A (ru) 2019-02-25
MX2017009532A (es) 2018-04-10
JP2018504457A (ja) 2018-02-15
AU2020239699A1 (en) 2020-10-15
AU2019201799B2 (en) 2020-10-15
MX387817B (es) 2025-03-11
US20250213508A1 (en) 2025-07-03
ZA201704977B (en) 2022-12-21
US10231941B2 (en) 2019-03-19
US20180185307A1 (en) 2018-07-05
JP2021020929A (ja) 2021-02-18
US20180008565A1 (en) 2018-01-11
AU2016209244A1 (en) 2017-08-17
EP3247342A1 (en) 2017-11-29
US20190160031A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
JP6783247B2 (ja) ガン予防における短鎖脂肪酸の使用
US11759442B2 (en) Use of short chain fatty acids for the treatment and prevention of diseases and disorders
JP7688360B2 (ja) 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
JP2021514968A (ja) 微生物関連の免疫療法
JP2022078078A (ja) 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
CA3167386A1 (en) A bacterial composition for the treatment of cancer
HK40082664A (en) Use of short chain fatty acids in cancer prevention
CA2974510C (en) Use of short chain fatty acids in cancer prevention
HK1240857A1 (en) Use of short chain fatty acids in cancer prevention
JP2022177817A (ja) ケトン供与体を含む組成物
JP2024075031A (ja) ケトン供与体を含む組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200811

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200923

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201021

R150 Certificate of patent or registration of utility model

Ref document number: 6783247

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250